Video

Glaucoma 360: Accessible glaucoma care in 1 second (BELKIN Laser)

ICYMI: Daria Lemann Blumenthal, CEO of BELKIN Laser, Ltd., discusses the company's current initiative of developing an automated one-second laser therapy for glaucoma called direct selective laser trabeculoplasty (DSLT).


ICYMI: Daria Lemann Blumenthal, LLB, EMBA, CEO of BELKIN Laser, Ltd., discusses the company's current initiative of developing an automated one-second laser therapy for glaucoma called direct selective laser trabeculoplasty (DSLT), during the 2020 Glaucoma 360 meeting in San Francisco, California.

See more Glaucoma 360 coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
© 2025 MJH Life Sciences

All rights reserved.